Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
出版年份 2021 全文链接
标题
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
作者
关键词
-
出版物
Infectious Diseases and Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-09
DOI
10.1007/s40121-021-00419-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France
- (2019) Ludivine Demessine et al. Open Forum Infectious Diseases
- Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications
- (2019) Hanh Thi Pham et al. EXPERT OPINION ON PHARMACOTHERAPY
- Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks
- (2019) Rima K. Acosta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) Hans-Jürgen Stellbrink et al. Lancet HIV
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) David A Wohl et al. Lancet HIV
- Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study
- (2019) Beatriz López-Centeno et al. CLINICAL INFECTIOUS DISEASES
- Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
- (2019) Kristen Andreatta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women
- (2019) Cissy Kityo et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Weight gain and integrase inhibitors
- (2019) Allison Ross Eckard et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide
- (2018) Anthony T. Podany et al. AIDS
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
- (2018) Eric S Daar et al. Lancet HIV
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2018) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients
- (2018) Clotilde Allavena et al. PLoS One
- Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
- (2018) Emma D. Deeks DRUGS
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
- (2017) Joel E. Gallant et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
- (2017) Adam Trickey et al. Lancet HIV
- Sex, Age, Race and Intervention Type in Clinical Studies of HIV Cure: A Systematic Review
- (2015) Rowena E. Johnston et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Increasing trends in HIV prevalence among people aged 50 years and older
- (2014) Mary Mahy et al. AIDS
- Evaluation of the Effect of Cobicistat on theIn VitroRenal Transport and Cytotoxicity Potential of Tenofovir
- (2013) Kirsten M. Stray et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Virologic and immunologic response to HAART, by age and regimen class
- (2010) Keri N Althoff et al. AIDS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now